S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:BGNE

BeiGene Stock Forecast, Price & News

$347.69
-3.82 (-1.09%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$340.00
$353.99
50-Day Range
$339.00
$398.50
52-Week Range
$219.20
$426.56
Volume
125,284 shs
Average Volume
265,929 shs
Market Capitalization
$32.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.75
30 days | 90 days | 365 days | Advanced Chart
Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.


BeiGene logo

About BeiGene

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Headlines

Notable Beigene Insider Trades $750K In Company Stock
November 22, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
5,300
Year Founded
2010

Sales & Book Value

Annual Sales
$308.87 million
Book Value
$35.95 per share

Profitability

Net Income
$-1.60 billion
Net Margins
-122.41%
Pretax Margin
-125.54%

Debt

Price-To-Earnings

Miscellaneous

Free Float
85,075,000
Market Cap
$32.47 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

Social Links


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

861st out of 1,391 stocks

Pharmaceutical Preparations Industry

411th out of 669 stocks

Analyst Opinion: 1.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












BeiGene (NASDAQ:BGNE) Frequently Asked Questions

Is BeiGene a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BeiGene stock.
View analyst ratings for BeiGene
or view top-rated stocks.

How has BeiGene's stock been impacted by COVID-19?

BeiGene's stock was trading at $145.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BGNE shares have increased by 138.7% and is now trading at $347.69.
View which stocks have been most impacted by COVID-19
.

Are investors shorting BeiGene?

BeiGene saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 2,070,000 shares, a drop of 33.9% from the October 31st total of 3,130,000 shares. Based on an average trading volume of 235,600 shares, the short-interest ratio is presently 8.8 days.
View BeiGene's Short Interest
.

When is BeiGene's next earnings date?

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for BeiGene
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($4.46) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($4.70) by $0.24. BeiGene had a negative trailing twelve-month return on equity of 35.06% and a negative net margin of 122.41%.
View BeiGene's earnings history
.

What price target have analysts set for BGNE?

8 analysts have issued 12-month price objectives for BeiGene's stock. Their forecasts range from $190.00 to $431.00. On average, they expect BeiGene's share price to reach $356.88 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts' price targets for BeiGene
or view top-rated stocks among Wall Street analysts.

Who are BeiGene's key executives?

BeiGene's management team includes the following people:

What is John V. Oyler's approval rating as BeiGene's CEO?

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.55%), Primecap Management Co. CA (4.08%), Invesco Ltd. (3.28%), Temasek Holdings Private Ltd (3.12%), BlackRock Inc. (2.82%) and Wellington Management Group LLP (0.91%). Company insiders that own BeiGene stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for BeiGene
.

Which institutional investors are selling BeiGene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Capital Bank & Trust Co, Goldman Sachs Group Inc., Wellington Management Group LLP, Bellevue Group AG, Macquarie Group Ltd., Primecap Management Co. CA, and Baillie Gifford & Co.. Company insiders that have sold BeiGene company stock in the last year include Bros Advisors Lp Baker, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for BeiGene
or view top insider-selling stocks.

Which institutional investors are buying BeiGene stock?

BGNE stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Temasek Holdings Private Ltd, BlackRock Inc., BNP Paribas Asset Management Holding S.A., UBS Group AG, Deutsche Bank AG, Schonfeld Strategic Advisors LLC, and Caption Management LLC. Company insiders that have bought BeiGene stock in the last two years include Amgen Inc, and Ltd Beigene.
View insider buying and selling activity for BeiGene
or or view top insider-buying stocks.

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $347.69.

How much money does BeiGene make?

BeiGene has a market capitalization of $32.47 billion and generates $308.87 million in revenue each year. The company earns $-1.60 billion in net income (profit) each year or ($14.20) on an earnings per share basis.

How many employees does BeiGene have?

BeiGene employs 5,300 workers across the globe.

When was BeiGene founded?

BeiGene was founded in 2010.

What is BeiGene's official website?

The official website for BeiGene is www.beigene.com.

Where are BeiGene's headquarters?

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 861058958000 or via email at [email protected].


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.